Table 4

Factors affecting eradication rates in the first-line therapy

Group A (S10)Group B (T14)
Univariate analyses
 23S rRNA mutation (genotypic)
  No90.4% (331/366)†91.3% (336/368)‡
  Yes61.9% (26/42)†42.4% (14/33)‡
 Clarithromycin resistance (phenotypic)
  Susceptible90.7% (331/365)†91.5% (335/366)‡
  Resistant62.2% (28/45)†44.4% (16/36)‡
 Metronidazole resistance (phenotypic)
  Susceptible89.3% (276/309)89.5% (257/287)
  Resistant82.2% (83/101)81.7% (94/115)
 Amoxicillin resistance (phenotypic)
  Susceptible87.6% (353/403)87.2% (348/399)
  Resistant83.3% (5/6)100% (3/3)
 Clarithromycin and metronidazole resistance (phenotypic)
  CLA-S and Met-S91.1% (257/282)91.2% (248/272)
  CLA-S and Met-R89.2% (74/83)92.6% (87/94)
  CLA-R and Met-S70.4% (19/27)60% (9/15)
  CLA-R and Met-R50% (9/18)33.3% (7/21)
 Compliance (took at least 80% of the drugs)
  Yes89.5% (556/621)§89.5% (548/612)*
  No37.9% (11/29)§23.7% (9/38)*
 Gastric ulcer
  Present90.6% (125/138)84.8% (128/151)
  Absent87.7% (372/424)87.1% (359/412)
 Duodenal ulcer
  Present92.3% (132/143)90.3% (130/144)
  Absent87.1% (366/420)85.2% (358/420)
 Setting
  Hospital88.5% (347/392)88% (344/391)
  Community85.3% (220/258)82.2% (213/259)
 CYP2C19 polymorphism
  PM88% (66/75)94.8% (73/77)
  IM/EM87.8% (418/476)84.8% (408/481)
Multivariate analyses**, adjusted OR (95% CI), p value
 Compliance
Poor vs good
31.2 (5.7 to 171.7), <0.00158.2 (15.2 to 222.8), <0.001
 Clarithromycin
Resistance vs no resistance
5.6 (2.4 to 13.0), <0.00117.2 (6.0 to 49.0), <0.001
 Metronidazole
Resistance vs no resistance
2.0 (0.9 to 4.3), 0.0721.3 (0.6 to 3.2), 0.507
 CYP2C19 genotype
PM vs IM/EM
1.0 (0.4 to 2.9), 0.9480.2 (0.0 to 1.0), 0.046
 Setting
Community vs hospital
1.5 (0.7 to 3.4), 0.3322.4 (1.0 to 5.7), 0.06
  • †p<0.001; ‡p<0.001; §p<0.001; *p<0.001; ¶p<0.05.

  • **ORs in the multiple logistic regression models adjusted for clarithromycin resistance, metronidazole resistance, compliance, duodenal ulcer, gastric ulcer, setting, CYP2C19 polymorphism, age and gender.

  • 23S rRNA, 23S ribosomal RNA; CLA, clarithromycin; EM, extensive metaboliser; IM, intermediate metaboliser; Met, metronidazole; PM, poor metaboliser; R, resistant; S, susceptible; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.